The aforementioned experimental findings furnish robust evidence suggesting that PXN not only functions as a potential therapeutic target for HNSCC but also its expression level can be exploited as a biomarker for prognostication of patient outcomes, particularly in HPV-infected cases. Here, PXN is linked to head and neck squamous cell carcinoma.